

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

## SUPPLEMENTAL MATERIAL

Supplementary Table 1: Baseline characteristics of AASK participants with *APOL1* genotyping: 1) included in study population (n=480), 2) excluded from present analysis due to prevalent proteinuria or missing proteinuria data at baseline (n=213).

Characteristic	Study Population (n=480)	Excluded from analyses (n=213)	P-value
Age at randomization, years	55.8 ± 9.6	50.2 ± 11.6	<0.01
Female	194 (40%)	84 (39%)	0.87
<i>APOL1</i> high-risk status	82 (17%)	78 (37%)	<0.01
European ancestry, %	16.6 ± 13.7	16.8 ± 12.3	0.81
Current smoker	131 (27%)	64 (30%)	0.47
Systolic blood pressure, mmHg	148 ± 24	156 ± 23	<0.01
Body mass index, kg/m <sup>2</sup>	30.7 ± 6.6	32.0 ± 6.8	0.02
Baseline eGFR, ml/min/1.73 m <sup>2</sup>	52.6 ± 13.4	40.4 ± 13.5	<0.01
Total cholesterol, mg/dL	211 ± 43	212 ± 47	0.73
High-density lipoprotein, mg/dL	48 ± 16	47 ± 15	0.39
Serum albumin, g/dL	4.3 ± 0.3	4.1 ± 0.3	<0.01
Urine protein, g/g Cr	0.04 (0.02 to 0.08)	0.64 (0.36 to 1.31)	<0.01
Urine sodium, g/day	3.4 (2.2 to 4.5)	3.8 (2.5 to 5.0)	0.02
Randomized blood pressure goal			1.00
Low	243 (51%)	108 (51%)	
Usual	237 (49%)	105 (49%)	
Randomized blood pressure drug			0.84
Metoprolol	191 (40%)	80 (38%)	
Ramipril	198 (41%)	92 (43%)	
Amlodipine	91 (19%)	41 (19%)	

Values presented as mean ± standard deviation, median (interquartile range), or n (%)

Abbreviations: eGFR=estimated glomerular filtration rate.

*APOL1* high-risk defined as having 2 risk alleles and low-risk defined as having 0-1 risk alleles.